David A. Melnick's most recent trade in Spero Therapeutics Inc was a trade of 53,190 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Feb. 1, 2022.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Spero Therapeutics Inc | David A. Melnick | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2022 | 53,190 | 53,190 | - | - | Stock Option (Right to Buy) | |
| Spero Therapeutics Inc | David A. Melnick | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2022 | 38,014 | 62,081 (0%) | 0% | 0 | Common Stock | |
| Spero Therapeutics Inc | David A. Melnick | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Aug 2021 | 24,067 | 24,067 (0%) | 0% | 0 | Common Stock | |
| Spero Therapeutics Inc | David A. Melnick | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2021 | 57,432 | 57,432 | - | - | Stock Option (Right to Buy) |